Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miridesap in Healthy Japanese Subjects
NCT02953808Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of miridesap in amyloidosis (5 cohorts), sponsored by GSK. Primary endpoints: Number of subjects with adverse events (AE) and serious adverse events (SAE) at 29 days, Number of subjects with abnormalities in clinical laboratory parameters at 59 days and 11 more. Started Nov 2016; status: completed.
02
Drugs
miridesap
03
Conditions
amyloidosis
Beyond the preview
Go deeper on NCT02953808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953808.